中国临床药理学杂志

贝伐珠单抗联合紫杉醇和卡铂治疗晚期卵巢癌患者的临床研究

PDF下载

刘彦霞 ^1a , 邓立文 ^1a , 江利 ^1a , 贾菊花 ^1b , 韩克 ^1a

中国临床药理学杂志 | 临床与基础桥接研究 2025,41(9): 1213-1217

收起

中国临床药理学杂志 |临床与基础桥接研究 2025 , 41 (9) : 1213 -1217

贝伐珠单抗联合紫杉醇和卡铂治疗晚期卵巢癌患者的临床研究

全屏

刘彦霞^1a, 邓立文^1a, 江利^1a, 贾菊花^1b, 韩克^1a

作者信息

^1a.泰康仙林鼓楼医院，妇科，江苏南京 210036

^1b.泰康仙林鼓楼医院，药学部，江苏南京 210036

通讯作者:

韩克，主任医师 MP: 13952008625 E-mail: liuyanxiaaa1@163.com

作者简介:

刘彦霞（1975-），女，副主任医师，主要从事卵巢恶性肿瘤的临床诊疗工作

Clinical trial of bevacizumab combined with paclitaxel and carboplatin in the treatment of patients with advanced ovarian cancer

Yan-xia LIU^1a, Li-wen DENG^1a, Li JIANG^1a, Ju-hua JIA^1b, Ke HAN^1a

Affiliations

^1a.Department of Gynecology, Taikang Xianlin Gulou Hospital, Nanjing 210036, Jiangsu Province, China

^1b.Department of Pharmacy, Taikang Xianlin Gulou Hospital, Nanjing 210036, Jiangsu Province, China

出版时间: 2025-05-17 doi: 10.13699/j.cnki.1001-6821.2025.09.003

文章导航

摘要

收起

目的

观察贝伐珠单抗注射液联合紫杉醇注射剂和卡铂注射剂治疗晚期卵巢癌患者的临床疗效及安全性。

方法

将晚期卵巢癌患者随机分为对照组和试验组。对照组给予175 mg·m^-2紫杉醇，每3周1次，静脉滴注不少于3 h+0.3~0.4 g·m^-2卡铂，每3周1次，静脉滴注；试验组在对照组治疗的基础上，给予15 mg·kg^-1贝伐珠单抗，每3周1次，静脉滴注。2组患者均治疗6个疗程，每个疗程3周。比较2组患者的临床疗效、肿瘤标志物、血管相关因子、T淋巴细胞和miRNA-30水平、治疗期间的生存情况，以及安全性。

结果

试验组入组71例，脱落10例，最终有61例纳入统计分析；对照组入组70例，脱落10例，最终有60例纳入统计分析。治疗后，试验组和对照组的疾病缓解率分别为60.66%（37例/61例）和41.67%（25例/60例），在统计学上差异有统计学意义（P<0.05）。治疗后，试验组和对照组的分化簇133水平分别为（11.44±2.46）和（26.77±5.41）U·mL^-1，DEAD盒螺旋酶4水平分别为（13.55±3.48）和（33.16±5.46）U·mL^-1，miRNA-30b相对表达水平分别为1.03±0.07和1.15±0.08，miRNA-30c相对表达水平分别为1.09±0.05和1.22±0.06，在统计学上差异均有统计学意义（均P<0.05）。随访期间，试验组和对照组的全因死亡病例数分别为8例和11例，生存率分别为86.89%和81.67%，在统计学上差异均无统计学意义（均P>0.05）。2组患者发生的药物不良反应均以胃肠道反应、脱发、过敏和肝功能损伤为主。试验组和对照组的总药物不良反应发生率分别为55.74%和43.33%，在统计学上差异无统计学意义（P>0.05）。

结论

贝伐珠单抗注射液联合紫杉醇注射剂和卡铂注射剂治疗晚期卵巢癌患者的临床疗效显著优于紫杉醇注射剂联合卡铂注射剂，前者能够显著降低患者的肿瘤标志物水平，提高免疫功能，且未增加药物不良反应的发生率。

关键词

贝伐珠单抗注射液 / 紫杉醇注射剂 / 卡铂注射剂 / 晚期卵巢癌 / 肿瘤标志物 / 血管内皮生长因子 / 血管生成素酪氨酸激酶蛋白受体2 / microRNA-30 / 安全性评价

Abstract

收起

Objective

To observe the clinical efficacy and safety of bevacizumab injection combined with paclitaxel injection and carboplatin injection in the treatment of patients with advanced ovarian cancer.

Methods

Patients with advanced ovarian cancer were randomly divided into control group and treatment group. The control group was given 175 mg·m^-2 paclitaxel once every 3 weeks, the intravenous infusion was not less than 3 h + 0.3 - 0.4 g·m^-2 carboplatin once every 3 weeks, intravenous infusion. On the basis of control group, the treatment group was given 15 mg·kg^-1 bevacizumab once every 3 weeks, intravenous infusion. Two groups were treated for 6 courses with 3 weeks per course. The clinical efficacy, tumor markers, vascular related factors, T lymphocyte and miRNA-30 levels, survival during treatment and safety were compared between two groups.

Results

Treatment group was enrolled 71 cases, 10 cases dropped out, and 61 cases were finally included in the statistical analysis. Control group was enrolled 70 cases, 10 cases dropped out, and 60 cases were finally included in the statistical analysis. After treatment, the disease remission rates of treatment and control groups were 60.66% (37 cases/61 cases) and 41.67% (25 cases/60 cases) with statistically significant difference (P<0.05). After treatment, the cluster of differentiation 133 levels were (11.44±2.46) and (26.77±5.41) U·mL^-1, the DEAD-box helicase 4 levels were (13.55±3.48) and (33.16±5.46) U·mL^-1, the relative expression levels of miRNA-30b were 1.03±0.07 and 1.15±0.08, the relative expression levels of miRNA-30c were 1.09±0.05 and 1.22±0.06, the differences were statistically significant (all P<0.05). During follow-up, all-cause deaths of treatment and control groups were 8 and 11 cases, the survival rates were 86.89% and 81.67% (all P>0.05). The adverse drug reactions in both groups were mainly gastrointestinal reactions, alopecia, allergies and liver dysfunction. The total incidences of adverse drug reactions in the treatment and control groups were 55.74% and 43.33%, without significant difference (P>0.05).

Conclusion

Bevacizumab injection combined with paclitaxel injection and carboplatin injection has better clinical efficacy in the treatment of patients with advanced ovarian cancer than paclitaxel injection combined with carboplatin injection, the former can significantly reduce the levels of tumor markers, improve immune function, without increasing the incidence of adverse drug reactions.

Key words

bevacizumab injection / paclitaxel injection / carboplatin injection / advanced ovarian cancer / tumor markers / vascular endothelial growth factor / angiopoietin receptor tyrosine kinase protein 2 / microRNA-30 / safety evaluation

引用本文

刘彦霞, 邓立文, 江利, 贾菊花, 韩克. 贝伐珠单抗联合紫杉醇和卡铂治疗晚期卵巢癌患者的临床研究. 中国临床药理学杂志, 2025 , 41 (9) : 1213 -1217 . DOI: 10.13699/j.cnki.1001-6821.2025.09.003

Yan-xia LIU, Li-wen DENG, Li JIANG, Ju-hua JIA, Ke HAN. Clinical trial of bevacizumab combined with paclitaxel and carboplatin in the treatment of patients with advanced ovarian cancer[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (9) : 1213 -1217 . DOI: 10.13699/j.cnki.1001-6821.2025.09.003

基金

收起

江苏省卫生健康委员会科研基金资助项目(H2020010861)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

2025年第41卷第9期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.13699/j.cnki.1001-6821.2025.09.003

接收时间：2024-12-20
首发时间：2026-08-04
出版时间：2025-05-17

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2024-12-20

基金

江苏省卫生健康委员会科研基金资助项目(H2020010861)

作者信息

^1a.泰康仙林鼓楼医院，妇科，江苏南京 210036

^1b.泰康仙林鼓楼医院，药学部，江苏南京 210036

通讯作者:

韩克，主任医师 MP: 13952008625 E-mail: liuyanxiaaa1@163.com

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/10.13699/j.cnki.1001-6821.2025.09.003

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT